Queen Elizabeth II Health Sciences Center

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)	Hemic and Lymphatic Diseases, Neoplasms by Site, VEXAS syndrome, bone marrow disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, myelodysplastic syndrome, neoplasm	Active, not recruiting	Phase 2	2026-09-15	NCT06782373
Selinexor and Backbone Treatments of Multiple Myeloma Patients	Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Recruiting	Phase 1 / Phase 2	2026-07-15	NCT02343042
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Subcutaneous Emphysema, alpha 1-antitrypsin deficiency, hereditary disease, liver disorder, lung disorder, pulmonary emphysema, respiratory system disorder	Recruiting	Phase 3	2026-05-13	NCT05677971

Clinical trials